<img alt="" height="1" width="1" />Salix Liver-Failure Win Puts Spotlight on Xifaxan in IBSBioWorld OnlineTop-line news confirmed in September that both studies, TARGET 1 and TARGET 2, met primary and secondary endpoints in IBS. But opinions are split regarding ...<nobr></nobr> |